A new attack on Epstein-Barr fatigue: two capsules put to the test
NCT ID NCT04308278
First seen Aug 31, 2026 · Last updated Sep 01, 2026 · Updated 1 time
Summary
This trial tests whether two experimental capsules, 2LEBV and 2LXFS, can reduce fatigue and other symptoms in people with an Epstein-Barr virus infection. Participants take one capsule daily for six months, either one of the study drugs or a placebo. The study measures changes in fatigue using a standard questionnaire, comparing the drug groups against placebo. The goal is to see if these capsules offer a new way to manage the debilitating tiredness that often follows EBV infection.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Two experimental oral capsules, 2LEBV and 2LXFS, taken daily for six months
- What this could lead to
- If effective, these capsules could offer a new way to reduce chronic fatigue and other symptoms in people with Epstein-Barr virus infection, where current care only manages symptoms.
- What could go wrong
- This is a mid-stage trial with a modest number of participants, and the capsules may not outperform a placebo. The treatment is experimental, and its safety and effectiveness are not yet established.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 88 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2021
- Expected to finish
-
Aug 2028
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
12 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Pre-Inclusion Criteria: * Patients, male or female, aged 12 years and older, * Patient with fatigue for 1 month or more, * Patient with at least two other symptoms among the following: Long-lasting exhaustion even after light exertion, subfebrile state, fever, loss of appetite, nausea, angina, conjunctivis, sensitive cervical or axillary lymph nodes, erythematous and swollen tonsil, headaches, sore throat, myalgia, muscular weakness, arthralgia, splenomegaly, visual disorders, memory disorders, attention deficit disorders, sleep disorders, gastrointestinal disorders, breathing disorders, cardiovascular disorders. * Patient (and/or parents if necessary) agrees to perform serology for the study, * Patient (and/or parents if necessary) agrees to perform lymphocyte typing for the study during the pre-inclusion visit, * Patients (and/or parents if necessary) having the faculties to understand and respect the constraints of the study, * Signature of the Informed Consent Form by the patient (and/or parents if necessary). Inclusion Criteria: \- Patient who have a positive serology for EBV (IgG and/or IgM positive). Exclusion Criteria: * Patient who have received any treatment with the 2LEBV® or 2LXFS®, * Patients who have received any homeopathic treatment in the previous 2 months prior to the study, * Patients under immunosuppressive treatment, * Patient undergoing treatment for psychiatric disorders, * Patients having received immunotherapy or micro-immunotherapy during the last 3 months, * Patients with known lactose intolerance, * Pregnant or breastfeeding women, * Patients who participated in a clinical study in the previous 2-months period, * Patients (and/or parents of patients if necessary) who are not sufficiently motivated to engage on the total study follow-up period, or likely to travel or to move before the end of the study, * Patients with severe immunodeficiency disease requiring long term treatment (\*) or patients under chemotherapy or radiotherapy, * Patients under homeopathic or phytotherapy treatment, * Patients addicted to or using recreational drugs, * Patient under guardianship and/or curatorship, (\*) important renal or respiratory insufficiency, transplanted or grafted patients, HIV/AIDS, terminal cancer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBV infection are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
7 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Cabinet privé
RECRUITINGSchoten, 2900, Belgium
-
Private Practice
RECRUITINGAartselaar, 2630, Belgium
-
Private Practice
RECRUITINGBrussels, 1200, Belgium
-
Private Practice
RECRUITINGGhent, 9000, Belgium
-
Private practice
RECRUITINGMarche-en-Famenne, 6900, Belgium
-
Private practice
RECRUITINGStavelot, 4790, Belgium
-
Private practice
RECRUITINGWaregem, 8790, Belgium
-
Private practice of Dr Pieterjan DEBBAUT
ACTIVE_NOT_RECRUITINGHeule, Kortrijk, 8501, Belgium
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immune cells engineered to hunt viruses show promise for transplant kids
- Supercharged immune cells take on Drug-Resistant infections
- Donor cells take on Drug-Resistant viruses in new trial
- Could a safer drug replace standard antiviral for kidney transplant patients?
- New antibody shows promise against Post-Transplant virus threat
- Virus tracking in kidney transplants may spot hidden risks